^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
NPM1 Mutation Assay

Type:
Laboratory Developed Test
Related tests:
Evidence

News

over1year
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML (PRNewswire)
"Kronos Bio...and Invivoscribe, a global provider of diagnostic kits and services for oncology, today announced their agreement to develop a companion diagnostic (CDx) for use with Kronos Bio's investigational therapy, entospletinib....The diagnostic will screen for the NPM1 mutation, which is present in approximately one-third of all patients with AML....Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in second half of 2023."
Licensing / partnership • P3 data
|
NPM1 Mutation Assay
|
entospletinib (GS-9973)